Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Procaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 16/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.95 |
| ▸ | MEN1 | O00255 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | DRD2 | P14416 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Procaterol SCHEMBL1231478 | 1.00 | KDM4E (0.98) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL27971156 | 1.00 | KDM4E (0.98) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL29804927 | 1.00 | KDM4E (0.98) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL29429700 | 1.00 | KDM4E (0.98) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL29992718 | 0.99 | KDM4E (1.00) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL9737339 | 0.99 | KDM4E (1.00) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL29832201 | 0.99 | KDM4E (1.00) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL124726 | 0.99 | KDM4E (1.00) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL3244629 | 0.99 | ADRB2 (0.98) | KDM4EGAASMN1; SMN2HIF1AADRB2 | |
| Procaterol SCHEMBL4633 | 0.98 | ADRB2 (1.00) | KDM4EGAASMN1; SMN2HIF1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3747469-B1 | THERAPEUTIC AGENT FOR ASTHMA CONTAINING IL-6 INHIBITOR | KATO MOTOKAZU (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-12600772-B2 | Therapeutic agent for asthma containing IL-6 inhibitor | Kato, Motokazu (JP) | 2026-04-14 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| CN-117945996-A | Refining method of procaterol hydrochloride | 南京红太阳医药研究院有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| CN-101801359-A | Transdermal delivery device ensuring an increased release of active principle through a biological interface | TTI ELLEBEAU INC | 2010-08-11 | — | — | CN | disclosed |
| US-20080286349-A1 | SYSTEMS, DEVICES, AND METHODS FOR PASSIVE TRANSDERMAL DELIVERY OF ACTIVE AGENTS TO A BIOLOGICAL INTERFACE | ABRAMONTE, FRANK | 2008-11-20 | — | — | US | disclosed |
| EP-1551391-B1 | DRY SYRUP PREPARATION OF PROCATEROL COMPRISING ASCORBIC ACID AND CITRIC ACID | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1551391-A1 | DRY SYRUP PREPARATION OF PROCATEROL COMPRISING ASCORBINIC ACID AND CITRIC ACID | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035044-A1 | DRY SYRUP PREPARATION OF PROCATEROL COMPRISING ASCORBINIC ACID AND CITRIC ACID | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | WO | disclosed |
| WO-1991000085-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1991-01-10 | — | — | WO | disclosed |
| US-4973470-A | COMPRESSED MIXTURE OF WATER SENSITIVE DRUG, CELLULOSE, AND LUBRICANT | WARNER-LAMBERT COMPANY (US) | 1990-11-27 | — | — | US | disclosed |
| US-RE33024-E | Bronchodilating 8-hydroxy-5-(1R)-1-hydroxy-2-(N-((1R)-2-(p-methoxyphenyl)-1-methylethyl)-amino)ethyl) carbostyril and intermediates thereof | TANABE SEIYAKU CO. LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0147719-B1 | NOVEL CARBOSTYRIL DERIVATIVE AND PROCESS FOR PREPARING SAME | Tanabe Seiyaku Co., Ltd. (JP) | 1989-07-26 | — | — | EP | disclosed |
| US-4579854-A | ADRENERGIC STIMULANTS | TANABE SEIYAKU CO., LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ADRB2 4274/4885KDM4E 1756/4885GAA 156/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ADRB2 556/4885KDM4E 3590/4885GAA 12/4885 |
| US-20080286349-A1 | SYSTEMS, DEVICES, AND METHODS FOR PASSIVE TRANSDERMAL DELIVERY OF ACTIVE AGENTS TO A BIOLOGICAL INTERFACE | MMP1, CUTA, MMP8 | ADRB2 3496/4885KDM4E 4631/4885GAA 1663/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ADRB2 556/4885KDM4E 3590/4885GAA 12/4885 |
| US-12600772-B2 | Therapeutic agent for asthma containing IL-6 inhibitor | IL6, IL6ST, IL5 | ADRB2 647/4885KDM4E 991/4885GAA 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.